Disease phenotyping in chronic obstructive pulmonary disease: The neutrophilic endotype

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 2, 2016, Pages 91-99

  Russell, Derek W ^a   Wells, J Michael ^a   Blalock, J Edwin ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

chronic obstructive pulmonary disease; endotype; personalized medicine; phenotype; proline glycine proline

Indexed keywords

ACROLEIN; AZITHROMYCIN; LEUKOTRIENE A4 HYDROLASE; MYELOPEROXIDASE; PROLYLGLYCYLPROLIC ACID; ROFLUMILAST; STEROID; TRIPEPTIDE; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; HUMAN; NEUTROPHIL; NEUTROPHILIA; PHENOTYPE; PROTEIN DEGRADATION; REVIEW; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

AMINOPYRIDINES; AZITHROMYCIN; BENZAMIDES; CYCLOPROPANES; HUMANS; NEUTROPHILS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84957442355     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000238     Document Type: Review

References (53)

1. Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015; 385: 1789-1798.
2. Speizer FE, Ware JH. Exploring different phenotypes of COPD. N Engl J Med 2015; 373: 185-186.
3. Burgel PR, Paillasseur JL, Roche N. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int 2014; 2014: 420134.
4. Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med 2014; 35: 131-141.
5. Agusti A. The path to personalised medicine in COPD. Thorax 2014; 69: 857-864.
6. Agusti A. Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? Ann Am Thorac Soc 2013; 10 (Suppl): S125-S130.
7. Roy K, Smith J, Kolsum U, et al. COPD phenotype description using principal components analysis. Respir Res 2009; 10: 41.
8. Garcia-Aymerich J, Gomez FP, Anto JM, et al. Phenotypic characterization and course of chronic obstructive pulmonary disease in the PAC-COPD Study: design and methods. Arch Bronconeumol 2009; 45: 4-11.
9. Rennard SI, Vestbo J. The many ''small COPDs'': COPD should be an orphan disease. Chest 2008; 134: 623-627.
10. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008; 102: 367-376.
11. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
12. Al-Kassimi FA, Alhamad EH. A challenge to the seven widely believed concepts of COPD. Int J Chron Obstruct Pulmon Dis 2013; 8: 21-30.
13. Lange P, Celli B, Agusti A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373: 111-122.
14. Bhavani S, Tsai CL, Perusich S, et al. Clinical and immunological factors in emphysema progression: 5-year prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD). Am J Respir Crit Care Med 2015; 192: 1171-1178.
15. Stockley RA. Alpha1-antitrypsin review. Clin Chest Med 2014; 35: 39-50.
16. Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. Chronic Obstr Pulm Dis (Miami) 2015; 2: 23-34.
17. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013; 68: 670-676.
18. Valvi D, Mannino DM, Mullerova H, Tal-Singer R. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis 2012; 7: 173-182.
19. Mannino DM, Valvi D, Mullerova H, Tal-Singer R. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD 2012; 9: 359-366.
20. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
21. Polatli M, Cakir A, Cildag O, et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008; 26: 97-102.
22. Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One 2012; 7: e51048.
23. Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011; 140: 626-633.
24. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013; 143: 1302-1311.
25. Garnock-Jones KP. Roflumilast: a review in COPD. Drugs 2015; 75: 1645-1656.
26. Wells JM, Jackson PL, Viera L, et al. A randomized, placebo-controlled trial of roflumilast. Effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 934-942.
27. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker inCOPD: findings fromtheECLIPSEstudy. Respir Res2010; 11: 77.
28. Vlahos R, Bozinovski S, Hamilton JA, Anderson GP. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol Ther 2006; 112: 106-115.
29. van Beurden WJ, Wielders PL, Scheepers PJ, et al. Superoxide production by peripheral polymorphonuclear leukocytes in patients with COPD. Respir Med 2003; 97: 401-406.
30. Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 968-975.
31. Beeh KM, Kornmann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003; 123: 1240-1247.
32. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349-355.
33. Sin D, van Eeden SF. Neutrophil-mediated lung damage: a new COPD phenotype? Respiration 2012; 83: 103-105.
34. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
35. O'Reilly PJ, Jackson PL, Wells JM, et al. Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open 2013; 3: e004140.
36. Djekic UV, Gaggar A, Weathington NM. Attacking the multitiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009; 121: 132-146.
37. Wells JM, Gaggar A, Blalock JE. MMP generated matrikines. Matrix Biol 2015; 44-46: 122-129.
38. Hoonhorst SJ, Timens W, Koenderman L, et al. Increased activation of blood neutrophils after cigarette smoking in young individuals susceptible to COPD. Respir Res 2014; 15: 121.
39. Zhang J, He J, Xia J, et al. Delayed apoptosis by neutrophils from COPD patients is associated with altered Bak, Bcl-xl, and Mcl-1 mRNA expression. Diagn Pathol 2012; 7: 65.
40. Makris D, Vrekoussis T, Izoldi M, et al. Increased apoptosis of neutrophils in induced sputum of COPD patients. Respir Med 2009; 103: 1130-1135.
41. Polosukhin VV, Cates JM, Lawson WE, et al. Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 317-327.
42. Overbeek SA, Braber S, Koelink PJ, et al. Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One 2013; 8: e55612.
43. Abdul Roda M, Fernstrand AM, Redegeld FA, et al. The matrikine PGP as a potential biomarker in COPD. Am J Physiol Lung Cell Mol Physiol 2015; 308: L1095-L1101.
44. Hardison MT, Brown MD, Snelgrove RJ, et al. Cigarette smoke enhances chemotaxis via acetylation of proline-glycine-proline. Front Biosci (Elite Ed) 2012; 4: 2402-2409.
45. Ten Hoeve AL, Roda MA, Redegeld F, et al. Proline-glycine-proline as a potential biomarker in chronic obstructive pulmonary disease and cystic fibrosis. Tanaffos 2012; 11: 12-15.
46. Gaggar A, Rowe SM, Matthew H, Blalock JE. Proline-glycine-proline (PGP) and high mobility group box protein-1 (HMGB1): potential mediators of cystic fibrosis airway inflammation. Open Respir Med J 2010; 4: 32-38.
47. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006; 12: 317-323.
48. O'Reilly P, Jackson PL, Noerager B, et al. N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD. Respir Res 2009; 10: 38.
49. Abdul Roda M, Sadik M, Gaggar A, et al. Targeting prolyl endopeptidase with valproic acid as a potential modulator of neutrophilic inflammation. PLoS One 2014; 9: e97594.
50. Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010; 330: 90-94.
51. Wells JM, O'Reilly PJ, Szul T, et al. An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 190: 51-61.
52. van Houwelingen AH, Weathington NM, Verweij V, et al. Induction of lung emphysema is prevented by L-arginine-threonine-arginine. FASEB J 2008; 22: 3403-3408.
53. Braber S, Koelink PJ, Henricks PA, et al. Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol 2011; 300: L255-L265.